MadagascarTuberculosis profile
Population  2014 24 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 12 (8.7–16) 51 (37–68)
Mortality (HIV+TB only) 0.48 (0.39–0.58) 2 (1.7–2.4)
Prevalence  (includes HIV+TB) 96 (50–160) 406 (214–659)
Incidence  (includes HIV+TB) 55 (49–62) 235 (207–264)
Incidence (HIV+TB only) 2.2 (1.7–2.8) 9.5 (7.4–12)
         
Case detection, all forms (%) 51 (46–58)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.49 (0.13–1.3) 3.9 (0.48–13)
MDR-TB cases among notified pulmonary
TB cases
100 (27–260) 93 (11–320)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 18 825   1 562
Pulmonary, clinically diagnosed 2 093   328
Extrapulmonary 5 658    
       
Total new and relapse 28 466    
Previously treated, excluding relapses 470    
Total cases notified 28 936    
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 492 (21%) 492
Laboratory-confirmed RR-/MDR-TB cases     27
Patients started on MDR-TB treatment ***     11
TB/HIV 2014 Number (%)
TB patients with known HIV status 6 606 (23)
HIV-positive TB patients 98 (1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 98 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (82) 24 182
Previously treated cases registered in 2013 (75) 2 243
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 5
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 3.7
% Funded domestically 5%
% Funded internationally 95%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-05 Data: www.who.int/tb/data